Japer Therapeutics Warrants
JSPRW
5 hedge funds and large institutions have $626K invested in Japer Therapeutics Warrants in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
1% more capital invested
Capital invested by funds: $619K → $626K (+$6.77K)
0.21% more ownership
Funds ownership: 20.52% → 20.73% (+0.21%)
0% more funds holding
Funds holding: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$7.48K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
1
Cowen and Company
New York
| $441K | +$7.48K | +35,499 | +2% |
|
2
Walleye Capital
New York
| $119K | – | – | – |
|
|
TCM
3
Tenor Capital Management
New York
| $50K | – | – | – |
|
|
ZA
4
Zazove Associates
Incline Village,
Nevada
| $12.4K | – | – | – |
|
5
Walleye Trading
New York
| $2.82K | – | – | – |
|
JSPRW Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q3 2024, worth a combined $626K — up 1.1% from $619K a quarter earlier.
Fund positioning in JSPRW was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Cowen and Company, adding an estimated $7.48K.
- 5 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $626K of Japer Therapeutics Warrants stock for Q3 2024, up 1.1% quarter-over-quarter.
- 0 funds opened new Japer Therapeutics Warrants positions in Q3 2024 and 0 closed out.
- The largest Japer Therapeutics Warrants buyer in Q3 2024 was Cowen and Company, an estimated $7.48K added.
Based on aggregated 13F filings for Q3 2024.